NeuVax: Difference between revisions
Content deleted Content added
m →Clinical trials: another try with DOI.. |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:NeuVax_Logo.jpg|thumb|right|]] |
[[File:NeuVax_Logo.jpg|thumb|right|]] |
||
'''NeuVax''', developed by [[Galena Biopharma]], Inc., is a peptide-based [[Cancer vaccine|vaccine]] aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve [[remission]] after standard of care treatment (e.g., surgery, [[radiation]], [[chemotherapy]]).<ref> |
'''NeuVax''', developed by [[Galena Biopharma]], Inc., is a peptide-based [[Cancer vaccine|vaccine]] aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve [[remission]] after standard of care treatment (e.g., surgery, [[radiation]], [[chemotherapy]]).<ref>{{cite journal |doi=10.1002/cncr.25586}}</ref> It consists of the E75 synthetic peptide initially isolated from [[HER2/neu]] proto-oncogene combined with the immune adjuvant, granulocyte macrophage colony stimulating factor (rhGM-CSF from yeast).<ref>{{cite journal |pmid=18392824}}</ref> NeuVax works by harnessing the patient’s own immune system to seek out and attack any residual cancer cells that express HER2/neu, a protein associated with tumors in [[Breast cancer|breast]], [[Ovarian cancer|ovarian]], [[Pancreatic cancer|pancreatic]], [[Colon cancer|colon]], [[Bladder cancer|bladder]] and [[Prostate cancer|prostate]] cancers.<ref>{{cite journal |doi=10.1586/erv.10.167}}</ref> |
||
==Clinical trials== |
==Clinical trials== |
||
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials.<ref>{{cite |
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials.<ref>{{cite journal |doi=10.1002/cncr.26574}}</ref> As a result, two additional NeuVax trials underway are: (1) a 700 patient Phase 3 trial for FDA approval<ref>{{ClinicalTrialsGov|NCT01479244|Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)}}</ref> and (2) a 300 patient Phase 2 trial studying the combination of NeuVax and Herceptin® (trastuzumab).<ref name=forbes>{{cite news |last=Marcial |first=Gene |title=Roche Accelerates Defense Strategy to Protect Breast-Cancer Drug Herceptin's Turf |work=Forbes |date=March 15, 2012 |url=http://www.forbes.com/sites/genemarcial/2012/03/15/roche-accelerates-defense-strategy-to-protect-breast-cancer-drug-herceptins-turf/ |accessdate=22 April 2012}}</ref> |
||
==References== |
==References== |
||
Revision as of 02:21, 2 September 2012
NeuVax, developed by Galena Biopharma, Inc., is a peptide-based vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve remission after standard of care treatment (e.g., surgery, radiation, chemotherapy).[1] It consists of the E75 synthetic peptide initially isolated from HER2/neu proto-oncogene combined with the immune adjuvant, granulocyte macrophage colony stimulating factor (rhGM-CSF from yeast).[2] NeuVax works by harnessing the patient’s own immune system to seek out and attack any residual cancer cells that express HER2/neu, a protein associated with tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers.[3]
Clinical trials
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials.[4] As a result, two additional NeuVax trials underway are: (1) a 700 patient Phase 3 trial for FDA approval[5] and (2) a 300 patient Phase 2 trial studying the combination of NeuVax and Herceptin® (trastuzumab).[6]
References
- ^ . doi:10.1002/cncr.25586.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . PMID 18392824.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1586/erv.10.167.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ . doi:10.1002/cncr.26574.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ Clinical trial number NCT01479244 for "Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)" at ClinicalTrials.gov
- ^ Marcial, Gene (March 15, 2012). "Roche Accelerates Defense Strategy to Protect Breast-Cancer Drug Herceptin's Turf". Forbes. Retrieved 22 April 2012.